HCC-TAG Conference | Conference

Biomarkers, Patient Factors Inform HCC Treatment Decisions Beyond Frontline Setting

March 3rd 2020

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

El-Khoueiry Forecasts Future of HCC Treatment Paradigm

March 3rd 2020

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.

Recent Approvals, Collaborative Care Model Spark Change in HCC Treatment

March 2nd 2020

Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.

Dr. Salem on Locoregional Therapy Versus Systemic Therapy in HCC

March 2nd 2020

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.

Dr. Singal on the Importance of Early Diagnosis in HCC

March 2nd 2020

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Immunotherapy Combinations Show Promise in Advanced HCC

March 2nd 2020

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Evidence Illustrates Multidisciplinary Care Is Standard in HCC

March 1st 2020

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Pillai Reflects on Achieved Goals at Inaugural HCC-TAG Conference

March 1st 2020

Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm

Dr. Hoshida on Molecular Subtyping in HCC

March 1st 2020

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

Dr. Pinato on Biomarker Challenges in HCC

March 1st 2020

David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.

x